Literature DB >> 27121880

Clinical trials in nasopharyngeal carcinoma-past, present and future.

Cheng Xu1, Yu-Pei Chen1, Jun Ma2.   

Abstract

Nasopharyngeal carcinoma (NPC) has an age-adjusted incidence for both sexes with greater frequency in some endemic regions, especially the southern China. Genetic, ethnic, environmental factors and Epstein-Barr virus (EBV) infection might take part in the cause of the disease. Based on the understanding and research progresses, we have had a further step among the diagnosis and prognosis of the disease. Meanwhile, a numerous clinical trials aiming to pick out the most suitable therapeutic choice are carried on from past till now. The purpose of this review is to summarize therapeutic approaches from past RCTs, introduce hot topics at present, and explore the development trend in the future. Applying appropriate combining procedures of radiotherapy and chemotherapy with developments in gene therapy and immunotherapy, the outcomes in the future might be widely improved.

Entities:  

Keywords:  Nasopharyngeal carcinoma (NPC); chemotherapy; clinical trials; radiotherapy

Mesh:

Year:  2016        PMID: 27121880     DOI: 10.21037/cco.2016.03.12

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  9 in total

1.  Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.

Authors:  Ying Lu; Haixin Huang; Hui Yang; Dagui Chen; Sibei Wu; Zhou Jiang; Rensheng Wang
Journal:  Cell Cycle       Date:  2017-07-11       Impact factor: 4.534

2.  Salinomycin may inhibit the cancer stem-like populations with increased chemoradioresistance that nasopharyngeal cancer tumorspheres contain.

Authors:  Gong Zhang; Shuping Zhang; Jinjin Ren; Chunxiao Yao; Zhongren Zhao; Xiurong Qi; Xiaofeng Zhang; Shuye Wang; Lei Li
Journal:  Oncol Lett       Date:  2018-06-07       Impact factor: 2.967

3.  SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma.

Authors:  Yanzhang Luo; Tin Seak Mok; Xiuxian Lin; Wanling Zhang; Yizhi Cui; Jiahui Guo; Xing Chen; Tao Zhang; Tong Wang
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

4.  CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma.

Authors:  Susan Ling Ling Hoe; Lu Ping Tan; Norazlin Abdul Aziz; Kitson Liew; Sin-Yeang Teow; Fazlyn Reeny Abdul Razak; Yoon Ming Chin; Nurul Ashikin Mohamed Shahrehan; Tai Lin Chu; Noor Kaslina Mohd Kornain; Suat-Cheng Peh; Cheng Eng Koay; Kwok-Wai Lo; Munirah Ahmad; Ching-Ching Ng; Alan Soo-Beng Khoo
Journal:  Sci Rep       Date:  2017-09-28       Impact factor: 4.379

5.  Caffeic acid phenethyl ester suppressed growth and metastasis of nasopharyngeal carcinoma cells by inactivating the NF-κB pathway.

Authors:  Yushan Liang; Guofei Feng; Liang Wu; Suhua Zhong; Xiaoyu Gao; Yan Tong; Wanmeng Cui; Yongying Qin; WenQing Xu; Xue Xiao; Zhe Zhang; Guangwu Huang; Xiaoying Zhou
Journal:  Drug Des Devel Ther       Date:  2019-04-26       Impact factor: 4.162

6.  High expression of calreticulin indicates poor prognosis and modulates cell migration and invasion via activating Stat3 in nasopharyngeal carcinoma.

Authors:  Yaqian Han; Qianjin Liao; Heran Wang; Shan Rao; Pin Yi; Lu Tang; Yutong Tian; Linda Oyang; Hui Wang; Yingrui Shi; Yujuan Zhou
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

7.  Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region.

Authors:  Josiane M Dias; Iara V V Santana; Vinicius D da Silva; André L Carvalho; Lidia M R B Arantes
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

8.  Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report.

Authors:  Jun Jin; Jiahao Du; Yanwei Wu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

9.  Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.

Authors:  Zhichao Xue; Vivian Wai Yan Lui; Yongshu Li; Lin Jia; Chanping You; Xin Li; Wenying Piao; Hui Yuan; Pek Lan Khong; Kwok Wai Lo; Lydia Wai Ting Cheung; Victor Ho Fan Lee; Anne Wing Mui Lee; Sai Wah Tsao; Chi Man Tsang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.